All In Biotech

Drug Trial Radar · NCT07038382

A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

A Randomized, Controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of HLX79 (Human Sialidase Fusion Protein) in Combination With Rituximab Injection (HLX01, Anti-CD20 Antibody) Versus Placebo in Patients With Active Glomerulonephritis

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Aug 5, 2025

Primary completion

Jan 2027

Study completion May 2030

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this clinical trial is to evaluate the safety and tolerability of HLX79 in combination with HLX01 versus placebo in combination with HLX01 in the treatment of glomerulonephritis. The secondary objective are to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HLX79 and HLX01, the clinical efficacy, the dynamic changes of biomarkers of HLX79 in combination with HLX01 in the treatment of glomerulonephritis. The subjects will receive different doses of HLX79 (10, 20, or 30 mg/kg) or placebo, all in combination with HLX01. After the end of the first treatment period, subjects will enter a 20-week follow-up period and then undergo pre-second treatment period assessments. If the investigator determines that the subject does not require the second treatment period, the subject will continue in follow-up until completing the total 48-week follow-up period.

Conditions

  • Membranous Nephropathy
  • Lupus Nephritis (LN)

Interventions

  • HLX79 10mg/kg/Placebo+HLX01Drug

    Subjects with MN will receive HLX79 10mg/kg or placebo, combine with HLX01 375 mg/m2

  • HLX79 20mg/kg/Placebo + HLX01Drug

    Subjects with MN will receive HLX79 20mg/kg or placebo combined with HLX01 375 mg/m2

  • HLX79 30mg/kg/placebo+HLX01Drug

    Subjects with MN will receive HLX79 30mg/kg or placebo combined with HLX01 375 mg/m2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to TreatmentTime frame: 24 weeks

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua Changgung Hospital

    Beijing, China · Not yet recruiting

  • Peking University People's Hospital

    Beijing, China · Not yet recruiting

  • Xiangya Hospital Of Gentral South University

    Changsha, China · Not yet recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, China · Not yet recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China · Not yet recruiting

  • The First Affiliated Hospital Zhejiang University School Of Medicine

    Hangzhou, China · Not yet recruiting

  • The Second Hospital of Anhui Medical University

    Hefei, China · Not yet recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China · Not yet recruiting

  • Jiangxi Provincial People's Hospital

    Nanchang, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Not yet recruiting

  • Jiangsu Province Hospital

    Nanjing, China · Not yet recruiting

  • Zhongdong Hospital Southeast University

    Nanjing, China · Not yet recruiting

  • Shanghai General Hospital

    Shanghai, China · Recruiting

  • Renmin Hospital Of Wuhan University

    Wuhan, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi'an, China · Not yet recruiting

  • The First Affiliated Hospital Of Xiamen University

    Xiamen, China · Not yet recruiting

  • Su Bei People's Hospital

    Yangzhou, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.